Loading the section…

ADPT: financial statements from SEC — TradeAlmanac

ADPT

Adaptive Biotechnologies Corporation: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	71M	94M	59M	52M	46M	43M
Cost of revenue	19M	18M	18M	17M	17M	19M
Research and development	24M	24M	24M	24M	24M	25M
Selling, general and administrative	21M	18M	18M	17M	17M	18M
Operating expenses	90M	84M	84M	82M	79M	91M
Operating income	−19M	10M	−25M	−30M	−33M	−47M
Interest expense	3M	3M	3M	3M	3M	3M
Net income	−20M	10M	−26M	−30M	−32M	−46M
Earnings per share	−0.13	0.06	−0.17	−0.20	−0.22	−0.31
Earnings per share, diluted	−0.13	0.06	−0.17	−0.20	−0.22	−0.31
Weighted average shares	156M	152M	152M	149M	148M	147M
Weighted average shares, diluted	156M	163M	152M	149M	148M	147M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	78M	70M	55M	43M	51M	48M	38M	60M
Receivables	48M	50M	45M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−10M	−28M
Depreciation and amortisation	3M	4M
Share-based compensation	12M	12M
Capital expenditure	796,000	1M
Investing cash flow	9M	26M
Financing cash flow	8M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator